Clinical Trial Update: Comparing a 6-month vs Long-term Course of Rezvilutamide With ADT Plus Chemotherapy in mHSPC [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial comparing a 6-month versus long-term course of Rezvilutamide with ADT and chemotherapy in metastatic hormone-sensitive prostate cancer …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hormone-sensitive Prostate Cancer

Drugs mentioned

• Rezvilutamide (rezvilutamide)

Snippet

Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) | Phase 3 | Status: RECRUITING